GAVI facts and figures

230 million

If fully funded, GAVI will roll out the five-in-one pentavalent vaccine to 230 million additional children through to 2015.

Source: GAVI business plan 2010

MDG4

GAVI support for increased immunisation will make significant contributions to achieving Millennium Development Goal 4 to reduce child mortality.

Source: GAVI business plan 2010

74%

Hepatitis B vaccine coverage has risen to 74% in low-income countries compared with 17% in 2000.

Source: WHO Department of Immunisation, Vaccines and Biologicals’ estimates and projections, November 2011

296 million

Since its launch in 2000, GAVI support has resulted in the immunisation of 296 million children with the hepatitis B vaccine.

Source: WHO Department of Immunisation, Vaccines and Biologicals’ estimates and projections, November 2010

US$ 750 million

The Bill & Melinda Gates Foundation gave GAVI a start-up grant of US$ 750 million in 1999.

Source: GAVI Alliance data 2010

77 countries

77 GAVI-eligible countries have been approved for GAVI support for at least one vaccine.

Source: GAVI Alliance data, 2010

More than 60 countries

In 2011, more than 60 countries were co-financing new and underused vaccines.

Source: GAVI Alliance data, September 2012

US$ 7.2 billion

GAVI has committed US$ 7.2 billion in programme support to low-income countries until 2016.

Source: GAVI Alliance data November 2011

1.9 million

Since 2007, GAVI support has resulted in the immunisation of 1.9 million children with the rotavirus vaccine.

Source: WHO Department of Immunisation, Vaccines and Biologicals’ estimates and projections, November 2011

3.6 million

Since 2010, GAVI support has resulted in the immunisation of 3.6 million children with the pneumococcal vaccine.

Source: WHO Department of Immunisation, Vaccines and Biologicals’ estimates and projections, November 2011

124 million

Since its launch in 2000, GAVI support has resulted in the immunisation of 124 million children with the Haemophilus influenzae type b vaccine.

Source: WHO Department of Immunisation, Vaccines and Biologicals’ estimates and projections, November 2011

860,000

GAVI’s support for measles vaccine has averted 860,000 future deaths.

Source: WHO Department of Immunisation, Vaccines and Biologicals’ estimates and projections, November 2011

697,000

GAVI’s support for Haemophilus influenzae type b vaccine has averted 697,000 future deaths.

Source: WHO Department of Immunisation, Vaccines and Biologicals’ estimates and projections, November 2011

140,000

GAVI’s support for yellow fever vaccine has averted 140,000 future deaths.

Source: WHO Department of Immunisation, Vaccines and Biologicals’ estimates and projections, November 2010

474,000

GAVI’s support for pentavalent vaccine has averted 474,000 future deaths.

Source: WHO Department of Immunisation, Vaccines and Biologicals’ estimates and projections, November 2010

4 million

GAVI’s support for vaccines, including pneumococcal disease and rotavirus, through to 2015, could avert an additional four million future deaths.

Source: GAVI business plan 2010

245 million

GAVI support will result in the immunisation of 245 million additional children through to 2015.

Source: GAVI business plan 2010

90 million

GAVI support will result in the immunisation of 90 million additional children against pneumococcal disease (the leading cause of pneumonia) from 2011 to 2015.

Source: GAVI business plan 2010

50 million

GAVI support will result in the immunisation of 50 million additional children with rotavirus vaccine, the leading cause of diarrhoea, through to 2015.

Source: GAVI business plan 2010

370 million

Since its launch in 2000, GAVI support has contributed to the immunisation of an additional 370 million children in the world's poorest countries.

Source: WHO Department of Immunisation, Vaccines and Biologicals’ estimates and projections, November 2011

US$ 21 million

GAVI is investing more than US$ 21 million in civil society organisations in developing countries through to 2015.

Source: GAVI Alliance data 2011

1 in 5

One in five of all children who annually die before the age of five lose their lives to vaccine-preventable diseases.

Source: WHO

43 %

Forty-three percent of GAVI vaccines are produced by pharmaceutical companies based in emerging markets.

Source: GAVI Alliance data 2008

22 million

22 million children, aged under five, remain unimmunised in the world.

Source: WHO/UNICEF coverage estimates 1980-2009, revision July 2011

7 million

Providing pneumococcal vaccines in 40 low-income countries will avert up to seven million future deaths by 2030.

Source: GAVI Alliance data 2010

3.9 million

GAVI’s support for hepatitis B vaccine has averted 3,896,000 future deaths from 2000 to 2011

Source: WHO Department of Immunisation, Vaccines and Biologicals’ estimates and projections, November 2011

5.5 million

GAVI support to countries has contributed to averting more than five and a half million future deaths.

Source: WHO Department of Immunisation, Vaccines and Biologicals’ estimates and projections, November 2011